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Women can bear a bigger burden: ante- and
post-mortem evidence for reserve in the
face of tau
Leonardino A. Digma,1 John R. Madsen,1 Robert A. Rissman,1,2 Diane M. Jacobs,1
James B. Brewer1,3 and Sarah J. Banks1,4, for the Alzheimer’s Disease Neuroimaging
Initiative*
* Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.-
loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided
data but did not participate in analysis or writing of this report. A complete list of ADNI investigators can be found in Appendix I.
In this study, we aimed to assess whether women are able to withstand more tau before exhibiting verbal memory impairment.
Using data from 121 amyloid-b-positive Alzheimer’s Disease Neuroimaging Initiative participants, we fit a linear model with Rey
Auditory Verbal Learning Test score as the response variable and tau-PET standard uptake value ratio as the predictor and took
the residuals as an estimate of verbal memory reserve for each subject. Women demonstrated higher reserve (i.e. residuals), whether
the Learning (t¼ 2.78, P¼ 0.006) or Delay (t¼2.14, P¼ 0.03) score from the Rey Auditory Verbal Learning Test was used as a
measure of verbal memory ability. To validate these findings, we examined 662 National Alzheimer’s Coordinating Center partici-
pants with a C2/C3 score (Consortium to Establish a Registry for Alzheimer’s Disease) at autopsy. We stratified our National
Alzheimer’s Coordinating Center sample into Braak 1/2, Braak 3/4 and Braak 5/6 subgroups. Within each subgroup, we com-
pared Logical Memory scores between men and women. Men had worse verbal memory scores within the Braak 1/2 (Logical
Memory Immediate: b ¼ 5.9606 1.517, P< 0.001, Logical Memory Delay: b ¼ 5.7036 1.677, P¼ 0.002) and Braak 3/4
(Logical Memory Immediate: b ¼ 2.90060.938, P¼ 0.002, Logical Memory Delay: b ¼ 2.6726 0.955, P¼0.006) subgroups.
There were no sex differences in Logical Memory performance within the Braak 5/6 subgroup (Logical Memory Immediate: b ¼
0.3146 0.328, P¼0.34, Logical Memory Delay: b ¼ 0.19560.287, P¼ 0.50). Taken together, our results point to a sex-
related verbal memory reserve.
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Introduction
Cognitive reserve describes the phenomenon where
individuals vary in cognitive performance despite har-
bouring similar amounts of Alzheimer’s disease path-
ology (Stern, 2002). Cognitive reserve has been
attributed to factors such as education (Stern et al.,
1992), overall intellectual ability (Alexander et al.,
1997), diet (Scarmeas et al., 2006) and social network
size (Bennett et al., 2006).
Sex may also play a role in reserve, with women dem-
onstrating higher reserve in verbal memory (Beinhoff
et al., 2008, Chapman et al., 2011). This is supported by
a pair of recent imaging studies, which reported that
women, while expressing similar levels of neurodegenera-
tion (Sundermann et al., 2016a, b), outperform men in
verbal memory. Further evidence comes from an investi-
gation demonstrating that sex can moderate the relation-
ship between amyloid-b (Ab) and verbal memory
performance (Caldwell et al., 2017).
Recent studies have revealed sex differences in tau
pathology. Post-mortem data indicate that women have
more tau at autopsy (Liesinger et al., 2018; Oveisgharan
et al., 2018). Ante-mortem examination of brain tau is
now available through positron emission tomography
(PET) (Marquie´ et al., 2015). A recent tau-PET study
reported that, among cognitively normal individuals with
elevated Ab, women harboured more tau (Buckley et al.,
2019). A potential corollary to these findings is that
women can withstand more tau before exhibiting verbal
memory impairment. In other words, women may exhibit
more reserve, but this hypothesis has not been explored
in vivo.
A useful approach for estimating cognitive reserve is
the residual framework (Reed et al., 2010; Zahodne
et al., 2013; Hohman et al., 2016; van Loenhoud et al.,
2017). Under this framework, a model is fitted to the
data, where cognitive performance is the response vari-
able and Alzheimer’s disease pathology is the predictor.
This model provides a predicted level of cognition for a
given level of pathology. Those that display higher than
predicted cognitive performance (i.e. positive residual) can
be characterized as having high cognitive reserve and vice
versa.
Graphical Abstract
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In this study, we applied this residual approach to PET
and verbal memory data from Alzheimer’s Disease
Neuroimaging initiative (ADNI) to estimate reserve. We
then assessed sex differences in reserve, hypothesizing
that women would demonstrate higher reserve than men.
We further aimed to characterize how women’s verbal
memory advantage varies by disease stage. For validation,
we examined autopsy and verbal memory data subjects
from the National Alzheimer’s Coordinating Center
(NACC).
Methods and materials
Study 1: ADNI tau-PET analysis
ADNI sample
We included ADNI participants who underwent Ab-
PET, flortaucipir (FTP)-PET and magnetic resonance
imaging, completed the ADNI neuropsychological bat-
tery and had APOE genotyping. Recruitment details for
ADNI are detailed elsewhere (Aisen et al., 2010; Weiner
et al., 2017). We restricted our sample to Ab-positive
subjects (based on previously derived thresholds; Landau
et al., 2012, 2013) to focus on the Alzheimer’s disease
spectrum.
ADNI neuroimaging processing
For each participant, we downloaded the first available
FTP-PET in its most preprocessed form (Joshi et al.,
2009) and the magnetic resonance imaging acquired tem-
porally closest to this FTP-PET. Magnetic resonance
imaging was processed with FreeSurfer (Dale et al., 1999,
Fischl et al., 1999). FTP volumes were first co-registered
to each subject’s magnetic resonance imaging. Then,
standard uptake value ratio volumes were generated by
normalizing to average FTP signal in the cerebellar grey.
Regional tau values were derived from mean standard
uptake value ratio within each Desikan-Killiany region
(Desikan et al., 2006). Tau load was defined as the aver-
age regional tau from entorhinal, parahippocampal, fusi-
form, inferior temporal and middle temporal cortex (Jack
et al., 2017).
Ab pathology was assessed using summary cortical
standard uptake value ratio (whole cerebellum reference)
data generated by the Jagust Lab (Landau et al., 2012,
2013).
ADNI memory measures
To assess verbal memory, we used Rey Auditory Verbal
Learning Test (RAVLT) scores acquired closest in time to
the FTP-PET (time between FTP-PET and RAVLT date:
mean: 0.639 years, SD: 0.783). We used the sum of
words across the first five trials (RAVLT Learning) and




We used Welch t-tests to assess sex differences in age,
education and summary Ab and v2 tests to examine sex
differences in e4 status.
Reserve analyses
We took a residual approach to estimate reserve. First,
we fit a linear regression model with RAVLT score as
the response variable and age, education, e4 status and
tau load as predictors. This model provides an individu-
al’s predicted RAVLT score for a certain level of tau
load. Since ‘reserve’ is defined as having better or worse
cognition than is predicted by pathology, we took each
individual’s residual in the model as an estimation of
their reserve. Welch t-tests were then performed to test
for a difference in residuals (i.e. reserve) between women
and men. This procedure was done for two separate
models, using either RAVLT Learning or RAVLT Delay
as the response variable.
Subgroup stratified analysis
To further explore these sex differences in tau and verbal
memory, we stratified our sample into two groups: cogni-
tively normal participants [preclinical Alzheimer’s disease
(preAD)] and mild cognitive impairment/Alzheimer’s dis-
ease participants [prodromal/probable Alzheimer’s disease
(proAD)]. Within each subgroup, we performed the fol-
lowing linear model analyses. First, we assessed sex dif-
ferences in tau load, RAVLT Learning and RAVLT
Delay after correcting for age, education and e4 status.
Then, we tested for sex differences in RAVLT Learning
and RAVLT Delay, while controlling for age, education,
e4 status and tau load.
Study 2: NACC post-mortem
analysis
NACC sample
For NACC analyses, we utilized data from the December
2018 freeze. We included participants with a clinical
diagnosis of normal cognition, amnestic mild cognitive
impairment or dementia (with Alzheimer’s disease as pre-
sumptive etiology) at last clinical visit and autopsy data
within 5 years of that visit. Our sample was restricted to
individuals 60 years or older at baseline and had at least
two visits prior to autopsy. We selected only participants
with a Consortium to Establish a Registry for
Alzheimer’s Disease neocortical neuritic plaque rating of
C2 or C3, indicating moderate to frequent plaques
(Mirra et al., 1991), to focus on participants on the
Alzheimer’s disease spectrum and to parallel our ADNI
analyses, which included only Ab-positive individuals.
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NACC neuropsychology measures
The NACC neuropsychological battery does not include
the RAVLT or similar list-learning task, so we instead
used scores from the Logical Memory (LM) test, which
assesses immediate (LM Immediate) and 20-minute
delayed recall of a brief story (LM Delay). The memory




To assess sex differences in age, education and time be-
tween last clinical visit and death, we used Welch two-
sample t-tests. To compare carriage of the e4 allele be-
tween men and women, we used v2 tests.
Pathology analyses
We first stratified our NACC cohort into three sub-
groups: Braak 1/2, Braak 3/4 and Braak 5/6 subgroups.
We then used linear models to examine sex differences in
LM Immediate and LM Delay scores within each sub-
group. In these models, we corrected for time between
last clinical visit and death, age at clinical visit and e4
status.
Data availability
The ADNI demographic, genetic, neuroimaging and
neuropsychology data that were used in our analyses are
available for eligible users for access and download at
the ADNI data repository (adni.loni.usc.edu). The NACC
demographic, genetic, neuropathology and neuropsych-
ology data that were used can be accessed freely by eli-
gible researchers through the NACC website
(alz.washington.edu).
Results
Study 1: ADNI tau-PET analysis
Subject characteristics
A total of 121 ADNI participants met criteria for our
study. Summary statistics are displayed in Table 1.
Across the sample, women were younger [t(119) ¼
2.37, P¼ 0.02] and had fewer years of education
[t(119) ¼ 3.40, P< 0.001]. No sex difference in e4 sta-
tus [v2 (1) ¼ 0.0476; P¼ 0.83] was observed. In our
preAD group (23 men and 26 women), the women were
not different with respect to age [t(44) ¼ 1.50,
P¼ 0.14], education [t(47) ¼ 1.35, P¼ 0.18] or e4 sta-
tus [v2(1) ¼ 0.0137; P¼ 0.91]. In the proAD group (40
men and 32 women), the men were marginally older
than women [t(65) ¼ 1.77, P¼ 0.08] and had higher
education than proAD women [t(73) ¼ 3.21, P¼ 0.002]
but were not different with respect to e4 status [v2 (1) <
0.001; P> 0.99]. We observed no sex differences in sum-
mary Ab standard uptake value ratio across the whole
group [t(115) ¼ 0.946, P¼ 0.35], within the preAD
[t(46) ¼ 1.298, P¼ 0.20] or within proAD [t(65) ¼
0.376, P¼ 0.71].
Reserve analysis
We first fit a linear regression model with RAVLT
Learning as the response variable and with age, educa-
tion, e4 status and tau load as predictors. In this model
(R-squared of model: 0.258), age (b ¼ 0.591,
SE¼ 0.156, P< 0.001), e4 status (b ¼ 5.03, SE¼ 2.19,
P ¼ 0.02) and tau load (b ¼ 21.6, SE¼ 3.86,
P< 0.001) were independently associated with RAVLT
Learning. Education was not significantly associated with
RAVLT Learning (b¼ 0.681, SE¼ 0.414, P¼ 0.10).
Analysing the residuals with Welch’s t-tests revealed that
women had significantly higher residuals (i.e. more re-
serve) than men in the RAVLT Learning [t(111) ¼ 2.78,
P¼ 0.006] (Fig. 1B).
When this analysis was repeated with RAVLT Delay as
the response variable, rather than RAVLT Learning, simi-
lar results were observed (R-squared of model: 0.262).
Tau load (b ¼ 5.57, SE¼ 1.449, P< 0.001), age (b ¼
0.256, SE¼ 0.0574, P< 0.001), e4 status (b ¼ 2.41,
SE¼ 0.804, P ¼ 0.003) and education (b¼ 0.338,
SE¼ 0.152, P¼ 0.03) were related to RAVLT Delay.
Furthermore, analysis of the residuals demonstrated that
women also had higher reserve in this model [t(114) ¼
2.14, P¼ 0.04] (Fig. 1D).
The significant age difference between men and women
in our ADNI sample may have potentially confounded
the results of our reserve analysis. Thus, we re-performed
this analysis using a subset of our ADNI participants
(N¼ 106; 53 women, 53 men) that were matched for age
across sexes. In these age-matched analyses, we found
similar results.
Table 1 Demographic characteristics and memory
tests scores of participants included in ADNI tau-PET
analyses
Variable Women Men
Number (% of ADNI sample) 58 (47.9) 63 (52.1)
Age (years)* 76.7 (6.80) 79.7 (6.98)
Education (years)* 15.4 (2.41) 16.9 (2.46)
Number of (%) APOE e4 carriers 32 (55) 36 (57)
Race (% white) 94.8 96.8
Number of preAD 26 23
Number of proAD (MCI/Alzheimer’s disease) 32 (17/15) 40 (27/13)
RAVLT Learning 38.1 (14.1) 34.2 (12.0)
RAVLT Delay 5.14 (5.01) 3.97 (4.63)
Cells are formatted as mean (SD) unless otherwise noted.
MCI ¼ mild cognitive impairment.
*Significant difference (P< 0.05) between women and men across the entire sample.
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Subgroup stratified analysis
After correcting for age, education and e4 status, men
in the preAD group performed worse on RAVLT
Learning (b ¼ 6.75, SE¼ 3.16, P¼ 0.04) than women,
but comparably on RAVLT Delay (b ¼ 1.74,
SE¼ 1.41, P¼ 0.23). In addition, preAD men had less
tau load than women (b ¼ 0.0921, SE¼ 0.0362,
P¼ 0.01), after accounting for age, education and e4
status. Lastly, after correcting for age, education, e4
status and tau load, men performed marginally worse
on RAVLT Learning (b ¼ 6.54, SE¼ 3.42, P¼ 0.06)
but comparably on RAVLT Delay (b ¼ 1.76,
SE¼ 1.53, P¼ 0.26).
Within the proAD group, women and men did not
perform differently on RAVLT Learning (b ¼ 0.861,
SE¼ 2.64, P¼ 0.75) or RAVLT Delay (b¼ 0.281,
SE¼ 0.833, P¼ 0.74) after controlling for age,
education and e4 status. However, proAD men had
lower tau (b ¼ 0.191, SE¼ 0.0819, P¼ 0.02) than
women. In models controlling for age, education, e4
status and tau load, we found no sex differences in
RAVLT Learning (b ¼ 1.96, SE¼ 2.46, P¼ 0.43) or
RAVLT Delay performance (b ¼ 0.436, SE¼ 0.811,
P¼ 0.59).
Study 2: NACC post-mortem
analysis
Subject characteristics
There were 662 subjects in the NACC database who met
criteria for our study and had complete data. The sum-
mary statistics are presented in Table 2. There were no
sex differences in any demographic variables within the
Braak 1/2 group or within the Braak 3/4 group. In the
Figure 1 Women demonstrate higher reserve to tau than men. Scatter plots (A) between RAVLT Learning and tau load or (C)
between RAVLT Delay and tau load. RAVLT Learning, RAVLT Delay and tau load were regressed onto age, years of education and e4 status
before plotting. Here, tau load is the average of regional SUVRs from a set of Alzheimer’s disease-vulnerable regions in temporal cortex. The
boxplots with swarm plot overlays are residuals from a linear model predicting (B) RAVLT Learning or (D) RAVLT Delay from tau load, age,
years of education and e4 status. Women have significantly higher residuals than men. SUVRs ¼ Standard uptake value ratios.
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Braak 5/6 subgroup, there were differences in age [t(419)
¼ 3.447, P< 0.001] and education [t(446) ¼ 6.570,
P< 0.001], with women being older and men having
more educational attainment.
Pathology analysis
In the Braak 1/2 group, men had lower scores on both
the LM Immediate (b ¼ 5.960, SE¼ 1.517, P< 0.001)
and LM Delay (b ¼ 5.703, SE¼ 1.677, P¼ 0.001) after
controlling for age at clinical visit, time between last clin-
ical visit and death date, education and e4 status. In a
similar model within the Braak 3/4 group, we observed
similar results. Men had lower scores on both LM
Immediate (b ¼ 2.900, SE¼ 0.938, P¼ 0.002) and LM
Delay (b ¼ 2.672, SE¼ 0.955, P¼ 0.006) (Fig. 2B and
D). In contrast, there were no sex differences in LM
Immediate (b ¼ 0.314, SE¼ 0.328, P¼ 0.34) or LM
Delay (b ¼ 0.195, SE¼ 0.287, P¼ 0.50) performance
within the severe Alzheimer’s disease group.
Discussion
We examined the relationship between sex, tau and verbal
memory in two different cohorts. Using ADNI data, we
applied a residual approach to estimate verbal memory re-
serve to tau pathology for each subject. We found that
women demonstrate higher verbal memory reserve. These
findings were validated using data from the NACC, where
we found that, among individuals within Braak 1/2 or
Braak 3/4, women had superior verbal memory. Taken to-
gether, our findings point to a sex-related verbal memory
reserve in the face of tau pathology.
The residual framework has been used extensively to
estimate reserve in the presence of brain changes associ-
ated with Alzheimer’s disease, such as neurodegeneration
and Ab (Hohman et al., 2016). We are aware of no
prior tau imaging studies that have explored sex-related
reserve. However, a series of recent studies suggested that
for similar levels of neurodegeneration, women performed
better on the RAVLT (Sundermann et al., 2016a, b).
Furthermore, another study found that the relationship
between Ab and RAVLT performance can be moderated
by sex (Caldwell et al., 2017). Our findings, in combin-
ation with these studies, indicate that women can sustain
more Alzheimer’s disease-related brain insult before show-
ing impaired RAVLT performance.
Apart from these imaging investigations, our results are
compatible with clinical and neuropsychological studies.
The verbal memory advantage for cognitively normal
women over men that we observed is consistent with
prior clinical investigations (Beinhoff et al., 2008,
Chapman et al., 2011). Furthermore, these studies, like
ours, showed that the advantage disappears with the pro-
gression of disease into dementia. Taken together, these
observations are congruent with the following interpret-
ation of how Alzheimer’s disease may progress in men
and women. Women start with a premorbid (i.e. prior to
the onset of Alzheimer’s disease pathology) advantage in
verbal memory abilities. During the early phases of tau
accumulation, memory abilities begin to decline in both
men and women, but the premorbid advantage for
women persists during this early phase, such that women
still perform superiorly in verbal memory for a given
level of tau (consistent with the apparent reserve that we
found in our study). Then, after a critical point in the
Alzheimer’s disease course, women begin to show a faster
decline in memory abilities and ultimately ‘catch up’ to
the memory impairment of men (in line with our lack of
verbal memory sex differences in the later AD stages).
The notion that women begin to decline more rapidly is
supported by in vivo studies showing that women pro-
gress faster from mild cognitive impairment to
Alzheimer’s disease and exhibit greater rates of
Table 2 Demographic characteristics and memory tests scores of participants included in NACC post-mortem
analyses
Braak 1/2, N5 46 Braak 3/4, N5 153 Braak 5/6, N5 463
Women Men Women Men Women Men
Number (% of Braak subgroup) 24 (52) 22 (48) 67 (44) 86 (56) 198 (43) 265 (57)
Age (years)c 84.9 (7.6) 84.4 (7.9) 85.9 (7.9) 83.7 (7.5) 82.9 (8.3)* 80.2 (8.1)
Education (years)c 15.0 (2.2) 15.1 (3.7) 15.1 (2.6) 15.5 (3.3) 14.2 (2.7) 16.0 (3.0)*
Number of (%) APOE e4 carriers 6 (25) 6 (27) 32 (48) 41 (48) 114 (58) 165 (62)
Race (% white) 100 95.5 98.5 93.0 89.9 95.5
Time between last clinical visit and death (years) 1.0 (0.8) 0.9 (0.8) 1.0 (0.9) 1.3 (0.9) 1.9 (1.4) 1.8 (1.3)
LM Immediatea,b 13.8 (5.3)* 8.0 (5.7) 8.7 (6.0)* 6.0 (5.7) 2.5 (3.7) 2.2 (3.0)
LM Delaya,b 12.5 (6.0)* 7.1 (6.3) 7.4 (6.2)* 4.9 (5.8) 1.3 (3.3) 1.2 (2.6)
Cells are formatted as mean (SD) unless otherwise noted.
aSignificant sex difference (P< 0.05) in the Braak 1/2 subgroup.
bSignificant sex difference (P< 0.05) in the Braak 3/4 subgroup.
cSignificant sex difference (P< 0.05) in the Braak 5/6 subgroup.
*Asterisk indicates higher value for women than men in that Braak category.
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Alzheimer’s disease-related cognitive decline (Lin et al.,
2015, Koran et al., 2017). Even further evidence comes
from a post-mortem study indicating that women are
more likely than men to express Alzheimer’s disease path-
ology as dementia (Barnes et al., 2005). Lastly, it was re-
cently reported that women are more susceptible to tau-
related hypometabolism (Ramanan et al., 2019), propos-
ing a potential underlying mechanism for this rapid de-
cline seen in women. Despite this burden of evidence,
however, our finding of a lack in verbal memory sex dif-
ferences among the more progressed stages of Alzheimer’s
disease can alternatively be attributed to a floor effect in
the verbal memory scores rather than a rapid decline in
women.
Our results from the NACC post-mortem analyses bolster
our conclusions from the ADNI tau-PET analyses. First, the
finding that, within Braak 1/2 and Braak 3/4 subgroups,
women performed better on verbal memory is consistent
with our interpretation of a sex-related reserve that we
derived from ADNI results. Furthermore, for our NACC
analyses, we used scores from a different memory test. The
harmony in results across ADNI and NACC analyses
indicates that the sex-related reserve is not specific to
RAVLT or LM but reserve in verbal memory abilities in
general.
The sex-related verbal memory reserve would have sev-
eral implications for clinical research. Much of our
understanding about the evolution of Alzheimer’s disease
is garnered from large observational cohorts, such as
ADNI and NACC. These cohorts often rely heavily on
assessing memory with verbal tests. Our findings contrib-
ute to the mounting evidence that it is critical to take
into account sex differences when considering cut points
for verbal memory tests (Sundermann et al., 2019). They
also endorse the use of additional non-verbal memory
tests in cohort studies of aging to better characterize the
memory changes associated with Alzheimer’s disease.
Although the residual approach has been shown to be
a suitable proxy for reserve by many groups, it clearly
does not account for all variability in cognition. For ex-
ample, men might have worse cognition than predicted
by tau because they have more co-morbidities, working
in concordance with tau, to impair cognition.
Incorporating in vivo markers for pathologies that
Figure 2 Among participants with similar levels of Alzheimer’s disease-related pathology, women perform better on verbal
memory tests. On the y-axis are raw scores for (A–C) LM Immediate and (D–F) LM Delay. Within the Braak 1/2 group and within the Braak
3/4 group, women had significantly higher scores on both LM Immediate and LM Delay. We observed no significant differences in LM score in the
Braak 5/6 group.
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commonly co-occur with Alzheimer’s disease would be
helpful to further characterize sex differences in the abil-
ity to tolerate tau.
Though this study is unable to fully explain the under-
pinnings of reserve, it demonstrates that sex plays a role
in conferring apparent cognitive reserve in the face of
tau. As such, we feel these results and others call for the
end of treating sex as a variable of no interest and, in-
stead, suggest thoughtful consideration into the role of
sex in the expression of Alzheimer’s disease.
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Appendix I
ADNI Investigators: Michael Weiner, MD (UC San
Francisco, Principal Investigator, Executive Committee);
Paul Aisen, MD (UC San Diego, ADCS PI and Director of
Coordinating Center Clinical Core, Executive Committee,
Clinical Core Leaders); Ronald Petersen, MD, PhD (Mayo
Clinic, Rochester, Executive Committee, Clinical Core
Leader); Clifford R. Jack, Jr., MD (Mayo Clinic, Rochester,
Executive Committee, MRI Core Leader); William Jagust,
MD (UC Berkeley, Executive Committee; PET Core
Leader); John Q. Trojanowki, MD, PhD (U Pennsylvania,
Executive Committee, Biomarkers Core Leader); Arthur W.
Toga, PhD (USC, Executive Committee, Informatics Core
Leader); Laurel Beckett, PhD (UC Davis, Executive
Committee, Biostatistics Core Leader); Robert C. Green,
MD, MPH (Brigham and Women’s Hospital, Harvard
Medical School, Executive Committee and Chair of Data
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and Publication Committee); Andrew J. Saykin, PsyD
(Indiana University, Executive Committee, Genetics Core
Leader); John Morris, MD (Washington University St.
Louis, Executive Committee, Neuropathology Core
Leader); Leslie M. Shaw (University of Pennsylvania,
Executive Committee, Biomarkers Core Leader); Enchi Liu,
PhD (Janssen Alzheimer Immunotherapy, ADNI 2 Private
Partner Scientific Board Chair); Tom Montine, MD, PhD
(University of Washington); Ronald G. Thomas, PhD (UC
San Diego); Michael Donohue, PhD (UC San Diego); Sarah
Walter, MSc (UC San Diego); Devon Gessert (UC San
Diego); Tamie Sather, MS (UC San Diego,); Gus Jiminez,
MBS (UC San Diego); Danielle Harvey, PhD (UC Davis;);
Michael Donohue, PhD (UC San Diego); Matthew
Bernstein, PhD (Mayo Clinic, Rochester); Nick Fox, MD
(University of London); Paul Thompson, PhD (USC School
of Medicine); Norbert Schuff, PhD (UCSF MRI); Charles
DeCArli, MD (UC Davis); Bret Borowski, RT (Mayo
Clinic); Jeff Gunter, PhD (Mayo Clinic); Matt Senjem, MS
(Mayo Clinic); Prashanthi Vemuri, PhD (Mayo Clinic);
David Jones, MD (Mayo Clinic); Kejal Kantarci (Mayo
Clinic); Chad Ward (Mayo Clinic); Robert A. Koeppe, PhD
(University of Michigan, PET Core Leader); Norm Foster,
MD (University of Utah); Eric M. Reiman, MD (Banner
Alzheimer’s Institute); Kewei Chen, PhD (Banner
Alzheimer’s Institute); Chet Mathis, MD (University of
Pittsburgh); Susan Landau, PhD (UC Berkeley); Nigel J.
Cairns, PhD, MRCPath (Washington University St. Louis);
Erin Householder (Washington University St. Louis); Lisa
Taylor Reinwald, BA, HTL (Washington University St.
Louis); Virginia Lee, PhD, MBA (UPenn School of
Medicine); Magdalena Korecka, PhD (UPenn School
of Medicine); Michal Figurski, PhD (UPenn School of
Medicine); Karen Crawford (USC); Scott Neu, PhD (USC);
Tatiana M. Foroud, PhD (Indiana University); Steven
Potkin, MD UC (UC Irvine); Li Shen, PhD (Indiana
University); Faber Kelley, MS, CCRC (Indiana University);
Sungeun Kim, PhD (Indiana University); Kwangsik Nho,
PhD (Indiana University); Zaven Kachaturian, PhD
(Khachaturian, Radebaugh & Associates, Inc and
Alzheimer’s Association’s Ronald and Nancy Reagan’s
Research Institute); Richard Frank, MD, PhD (General
Electric); Peter J. Snyder, PhD (Brown University); Susan
Molchan, PhD (National Institute on Aging/National
Institutes of Health); Jeffrey Kaye, MD (Oregon Health and
Science University); Joseph Quinn, MD (Oregon Health
and Science University); Betty Lind, BS (Oregon Health and
Science University); Raina Carter, BA (Oregon Health
and Science University); Sara Dolen, BS (Oregon Health and
Science University); Lon S. Schneider, MD (University of
Southern Califor nia); Sonia Pawluczyk, MD (University
of Southern California); Mauricio Beccera, BS (University of
Southern California); Liberty Teodoro, RN (University of
Southern California); Bryan M. Spann, DO, PhD
(University of Southern California); James Brewer, MD,
PhD (University of California San Diego); Helen
Vanderswag, RN (University of California San Diego);
Adam Fleisher, MD (University of California San Diego);
Judith L. Heidebrink, MD, MS (University of Michigan);
Joanne L. Lord, LPN, BA, CCRC (University of Michigan);
Ronald Petersen, MD, PhD (Mayo Clinic, Rochester); Sara
S. Mason, RN (Mayo Clinic, Rochester); Colleen S. Albers,
RN (Mayo Clinic, Rochester); David Knopman, MD (Mayo
Clinic, Rochester); Kris Johnson, RN (Mayo Clinic,
Rochester); Rachelle S. Doody, MD, PhD (Baylor College of
Medicine); Javier Villanueva Meyer, MD (Baylor College of
Medicine); Munir Chowdhury, MBBS, MS (Baylor College
of Medicine); Susan Rountree, MD (Baylor College of
Medicine); Mimi Dang, MD (Baylor College of Medicine);
Yaakov Stern, PhD (Columbia University Medical
Center); Lawrence S. Honig, MD, PhD (Columbia
University Medical Center); Karen L. Bell, MD
(Columbia University Medical Center); Beau Ances, MD
(Washington University, St. Louis); John C. Morris,
MD (Washington University, St. Louis); Maria Carroll, RN,
MSN (Washington University, St. Louis); Sue Leon,
RN, MSN (Washington University, St. Louis); Erin
Householder, MS, CCRP (Washington University, St.
Louis); Mark A. Mintun, MD (Washington University, St.
Louis); Stacy Schneider, APRN, BC, GNP (Washington
University, St. Louis); Angela Oliver, RN, BSN, MSG;
Daniel Marson, JD, PhD (University of Alabama
Birmingham); Randall Griffith, PhD, ABPP (University of
Alabama Birmingham); David Clark, MD (University of
Alabama Birmingham); David Geldmacher, MD (University
of Alabama Birmingham); John Brockington, MD
(University of Alabama Birmingham); Erik Roberson,
MD (University of Alabama Birmingham); Hillel Grossman,
MD (Mount Sinai School of Medicine); Effie Mitsis, PhD
(Mount Sinai School of Medicine); Leyla deToledo-Morrell,
PhD (Rush University Medical Center); Raj C. Shah, MD
(Rush University Medical Center); Ranjan Duara, MD
(Wien Center); Daniel Varon, MD (Wien Center); Maria T.
Greig, HP (Wien Center); Peggy Roberts, CNA (Wien
Center); Marilyn Albert, PhD (Johns Hopkins University);
Chiadi Onyike, MD (Johns Hopkins University); Daniel
D’Agostino II, BS (Johns Hopkins University); Stephanie
Kielb, BS (Johns Hopkins University); James E. Galvin, MD,
MPH (New York University); Dana M. Pogorelec (New
York University); Brittany Cerbone (New York University);
Christina A. Michel (New York University); Henry Rusinek,
PhD (New York University); Mony J. de Leon, EdD (New
York University); Lidia Glodzik, MD, PhD (New York
University); Susan De Santi, PhD (New York University); P.
Murali Doraiswamy, MD (Duke University Medical
Center); Jeffrey R. Petrella, MD (Duke University
Medical Center); Terence Z. Wong, MD (Duke
University Medical Center); Steven E. Arnold, MD
(University of Pennsylvania); Jason H. Karlawish, MD
(University of Pennsylvania); David Wolk, MD (University
of Pennsylvania); Charles D. Smith, MD (University of
Kentucky); Greg Jicha, MD (University of Kentucky); Peter
Hardy, PhD (University of Kentucky); Partha Sinha, PhD
(University of Kentucky); Elizabeth Oates, MD (University
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of Kentucky); Gary Conrad, MD (University of Kentucky);
Oscar L. Lopez, MD (University of Pittsburgh); MaryAnn
Oakley, MA (University of Pittsburgh); Donna M. Simpson,
CRNP, MPH (University of Pittsburgh); Anton P.
Porsteinsson, MD (University of Rochester Medical Center);
Bonnie S. Goldstein, MS, NP (University of Rochester
Medical Center); Kim Martin, RN (University of Rochester
Medical Center); Kelly M. Makino, BS (University of
Rochester Medical Center); M. Saleem Ismail, MD
(University of Rochester Medical Center); Connie Brand,
RN (University of Rochester Medical Center); Ruth A.
Mulnard, DNSc, RN, FAAN (University of California,
Irvine); Gaby Thai, MD (University of California, Irvine);
Catherine Mc Adams Ortiz, MSN, RN, A/GNP (University
of California, Irvine); Kyle Womack, MD (University of
Texas Southwestern Medical School); Dana Mathews, MD,
PhD (University of Texas Southwestern Medical School);
Mary Quiceno, MD (University of Texas Southwestern
Medical School); Ramon Diaz Arrastia, MD, PhD
(University of Texas Southwestern Medical School);
Richard King, MD (University of Texas Southwestern
Medical School); Myron Weiner, MD (University of Texas
Southwestern Medical School); Kristen Martin Cook, MA
(University of Texas Southwestern Medical School);
Michael DeVous, PhD (University of Texas Southwestern
Medical School); Allan I. Levey, MD, PhD (Emory
University); James J. Lah, MD, PhD (Emory University);
Janet S. Cellar, DNP, PMHCNS BC (Emory University);
Jeffrey M. Burns, MD (University of Kansas, Medical
Center); Heather S. Anderson, MD (University of Kansas,
Medical Center); Russell H. Swerdlow, MD (University of
Kansas, Medical Center); Liana Apostolova, MD
(University of California, Los Angeles); Kathleen Tingus,
PhD (University of California, Los Angeles); Ellen Woo,
PhD (University of California, Los Angeles); Daniel H. S.
Silverman, MD, PhD (University of California, Los
Angeles); Po H. Lu, PsyD (University of California, Los
Angeles); George Bartzokis, MD (University of California,
Los Angeles); Neill R. Graff Radford, MBBCH, FRCP
(London) (Mayo Clinic, Jackson ville); Francine Parfitt,
MSH, CCRC (Mayo Clinic, Jacksonville); Tracy Kendall,
BA, CCRP (Mayo Clinic, Jacksonville); Heather Johnson,
MLS, CCRP (Mayo Clinic, Jacksonville); Martin R. Farlow,
MD (Indiana University); Ann Marie Hake, MD (Indiana
University); Brandy R. Matthews, MD (Indiana University);
Scott Herring, RN, CCRC (Indiana University); Cynthia
Hunt, BS, CCRP (Indiana University); Christopher H. van
Dyck, MD (Yale University School of Medicine); Richard E.
Carson, PhD (Yale University School of Medicine); Martha
G. MacAvoy, PhD (Yale University School of Medicine);
Howard Chertkow, MD (McGill Univ., Montreal Jewish
General Hospital); Howard Bergman, MD (McGill Univ.,
Montreal Jewish General Hospital); Chris Hosein, Med
(McGill Univ., Montreal Jewish General Hospital); Sandra
Black, MD, FRCPC (Sunnybrook Health Sciences, Ontario);
Dr. Bojana Stefanovic (Sunnybrook Health Sciences,
Ontario); Curtis Caldwell, PhD (Sunnybrook Health
Sciences, Ontario); Ging Yuek Robin Hsiung, MD, MHSc,
FRCPC (U.B.C. Clinic for AD & Related Disorders);
Howard Feldman, MD, FRCPC (U.B.C. Clinic for AD &
Related Disorders); Benita Mudge, BS (U.B.C. Clinic for AD
& Related Disorders); Michele Assaly, MA Past (U.B.C.
Clinic for AD & Related Disorders); Andrew Kertesz, MD
(Cognitive Neurology St. Joseph’s, Ontario); John Rogers,
MD (Cognitive Neurology St. Joseph’s, Ontario); Dick
Trost, PhD (Cognitive Neurology St. Joseph’s, Ontario);
Charles Bernick, MD (Cleveland Clinic Lou Ruvo Center
for Brain Health); Donna Munic, PhD (Cleveland Clinic
Lou Ruvo Center for Brain Health); Diana Kerwin, MD
(Northwestern University); Marek Marsel Mesulam,
MD (Northwestern University); Kristine Lipowski, BA
(Northwestern University); Chuang Kuo Wu, MD,
PhD (Northwestern University); Nancy Johnson, PhD
(Northwestern University); Carl Sadowsky, MD [Premiere
Research Inst (Palm Beach Neurology)]; Walter Martinez,
MD [Premiere Research Inst (Palm Beach Neurology)];
Teresa Villena, MD [Premiere Research Inst (Palm Beach
Neurology)]; Raymond Scott Turner, MD, PhD
(Georgetown University Medical Center); Kathleen
Johnson, NP (Georgetown University Medical Center);
Brigid Reynolds, NP (Georgetown University Medical
Center); Reisa A. Sperling, MD (Brigham and Women’s
Hospital); Keith A. Johnson, MD (Brigham and Women’s
Hospital); Gad Marshall, MD (Brigham and Women’s
Hospital); Meghan Frey (Brigham and Women’s Hospital);
Jerome Yesavage, MD (Stanford University); Joy L. Taylor,
PhD (Stanford University); Barton Lane, MD (Stanford
University); Allyson Rosen, PhD (Stanford University);
Jared Tinklenberg, MD (Stanford University); Marwan N.
Sabbagh, MD (Banner Sun Health Research Institute);
Christine M. Belden, PsyD (Banner Sun Health Research
Institute); Sandra A. Jacobson, MD (Banner Sun Health
Research Institute); Sherye A. Sirrel, MS (Banner Sun Health
Research Institute); Neil Kowall, MD (Boston University);
Ronald Killiany, PhD (Boston University); Andrew E.
Budson, MD (Boston University); Alexander Norbash, MD
(Boston University); Patricia Lynn Johnson, BA (Boston
University); Thomas O. Obisesan, MD, MPH (Howard
University); Saba Wolday, MSc (Howard University);
Joanne Allard, PhD (Howard University); Alan Lerner,
MD (Case Western Reserve University); Paula Ogrocki,
PhD (Case Western Reserve University); Leon Hudson,
MPH (Case Western Reserve University); Evan Fletcher,
PhD (University of California, Davis Sacramento); Owen
Carmichael, PhD (University of California, Davis
Sacramento); John Olichney, MD (University of California,
Davis Sacramento); Charles DeCarli, MD (University of
California, Davis Sacramento); Smita Kittur, MD
(Neurological Care of CNY); Michael Borrie, MB ChB
(Parkwood Hospital); T. Y. Lee, PhD (Parkwood Hospital);
Dr. Rob Bartha, PhD (Parkwood Hospital); Sterling
Johnson, PhD (University of Wisconsin); Sanjay Asthana,
MD (University of Wisconsin); Cynthia M. Carlsson, MD
(University of Wisconsin); Steven G. Potkin, MD (University
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of California, Irvine BIC); Adrian Preda, MD (University
of California, Irvine BIC); Dana Nguyen, PhD
(University of California, Irvine BIC); Pierre Tariot, MD
(Banner Alzheimer’s Institute); Adam Fleisher, MD (Banner
Alzheimer’s Institute); Stephanie Reeder, BA (Banner
Alzheimer’s Institute); Vernice Bates, MD (Dent Neurologic
Institute); Horacio Capote, MD (Dent Neurologic Institute);
Michelle Rainka, PharmD, CCRP (Dent Neurologic
Institute); Douglas W. Scharre, MD (Ohio State University);
Maria Kataki, MD, PhD (Ohio State University); Anahita
Adeli, MD (Ohio State University); Earl A. Zimmerman,
MD (Albany Medical College); Dzintra Celmins, MD
(Albany Medical College); Alice D. Brown, FNP (Albany
Medical College); Godfrey D. Pearlson, MD (Hartford
Hosp, Olin Neuropsychiatry Research Center); Karen
Blank, MD (Hartford Hosp, Olin Neuropsychiatry
Research Center); Karen Anderson, RN (Hartford Hosp,
Olin Neuropsychiatry Research Center); Robert B. Santulli,
MD (Dartmouth Hitchcock Medical Center); Tamar J.
Kitzmiller (Dartmouth Hitchcock Medical Center); Eben S.
Schwartz, PhD (Dartmouth Hitchcock Medical Center);
Kaycee M. Sink, MD, MAS (Wake Forest University Health
Sciences); Jeff D. Williamson, MD, MHS (Wake Forest
University Health Sciences); Pradeep Garg, PhD (Wake
Forest University Health Sciences); Franklin Watkins, MD
(Wake Forest University Health Sciences); Brian R. Ott, MD
(Rhode Island Hospital); Henry Querfurth, MD (Rhode
Island Hospital); Geoffrey Tremont, PhD (Rhode Island
Hospital); Stephen Salloway, MD, MS (Butler Hospital);
Paul Malloy, PhD (Butler Hospital); Stephen Correia, PhD
(Butler Hospital); Howard J. Rosen, MD (UC San
Francisco); Bruce L. Miller, MD (UC San Francisco); Jacobo
Mintzer, MD, MBA (Medical University South Carolina);
Kenneth Spicer, MD, PhD (Medical University South
Carolina); David Bachman, MD (Medical University South
Carolina); Elizabether Finger, MD (St. Joseph’s Health
Care); Stephen Pasternak, MD (St. Joseph’s Health Care);
Irina Rachinsky, MD (St. Joseph’s Health Care); John
Rogers, MD (St. Joseph’s Health Care); Andrew Kertesz,
MD (St. Joseph’s Health Care); Dick Drost, MD (St.
Joseph’s Health Care); Nunzio Pomara, MD (Nathan Kline
Institute); Raymundo Hernando, MD (Nathan Kline
Institute); Antero Sarrael, MD (Nathan Kline Institute);
Susan K. Schultz, MD (University of Iowa College of
Medicine, Iowa City); Laura L. Boles Ponto, PhD (University
of Iowa College of Medicine, Iowa City); Hyungsub Shim,
MD (University of Iowa College of Medicine, Iowa City);
Karen Elizabeth Smith, RN (University of Iowa College of
Medicine, Iowa City); Norman Relkin, MD, PhD (Cornell
University); Gloria Chaing, MD (Cornell University); Lisa
Raudin, PhD (Cornell University); Amanda Smith, MD
(University of South Floriday: USF Health Byrd Alzheimer’s
Institute); Kristin Fargher, MD (University of South
Floriday: USF Health Byrd Alzheimer’s Institute); and
Balebail Ashok Raj, MD (University of South Floriday: USF
Health Byrd Alzheimer’s Institute).
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